Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
09 December 2022 | Story Rulanzen Martin | Photo Barend Nagel
From the left: Rulanzen Martin, Lacea Loader, Dr Nitha Ramnath, and Martie Nortjé.

Another year, another round of national and international awards for the Department of Communication and Marketing’s (DCM) campaigns and projects. This year saw DCM pick up an International Association of Business Communicators (IABC) Africa Silver Quill Award of Excellence for Communication Research for Narrative Building Storytelling. This project and subsequent award were in partnership with Development Communication Solutions (DevCom), led by Lacea Loader, Director: Communication and Marketing. 

During the 2022 annual Marketing, Advancement and Communication in Education (MACE) Excellence Awards, DCM won four excellence awards. Dr Nitha Ramnath, Deputy Director: Corporate Relations, won a Silver Award of Excellence for the 2021 Rector’s Concert, and a Bronze Award of Excellence for the 2022 Rector’s Concert. 

Lacea Loader and Martie Nortjé, Manager: Reputation, Brand and Marketing Management, won a Bronze Award of Excellence for the project ‘UFS – Our Story: The building and implementation of a brand narrative.’ Rounding up the UFS’ winning tally was Website Editor, Rulanzen Martin, who won a MACE Bronze Award of Excellence for the 2021 UFS Deaf Awareness Month (DAM) Campaign. The DAM campaign also received recognition during the 2021 IABC Silver Quill awards, where it won a Silver Quill Award of Excellence. 

Awards a perfect opportunity to benchmark 

“The awards give recognition to the communication efforts and endeavours undertaken by DCM as the strategic communication partner at the UFS; it also serves as a perfect opportunity to benchmark against peers and the industry. I am extremely proud of what the team has achieved,” says Loader.  “It is an honour when our projects receive awards, given the calibre of entries submitted for both the IABC and MACE awards programmes. The IABC awards programme is for all industries, while the MACE awards only recognise higher education institutions,” she says. 

For the 2022 MACE Excellence Awards, a total of 95 awards were awarded to 12 institutions from a total of 171 entries.

News Archive

Researchers receive study grant for research into Congo Fever
2015-03-10

UFS researchers will be contributing significantly to the search for a vaccine against the deadly tick-borne disease known as Congo Fever.

Prof Felicity Burt from the Department of Medical Microbiology and Virology was recently awarded a research grant by the National Health Laboratory Service (NHLS) to study candidate vaccines for Crimean-Congo heamorrhagic fever (CCHF) virus and other arboviruses.

Arboviruses are viruses transmitted by mosquitoes, ticks, or other arthropods.

Prof Burt is an internationally-recognised expert on the Crimean-Congo haemorrhagic fever (CCHF). The Crimean-Congo haemorrhagic fever (CCHF) virus is a tick-borne virus that is associated with severe haemorrhagic disease in South Africa and other parts of Africa, Asia, and eastern Europe. Her interests focus on medically significant viruses that are transmitted by ticks and mosquitoes. Her research group is involved in determining the immune responses that are induced by different viral proteins.

Crimean-Congo haemorrhagic fever (CCHF) virus, a tick- borne virus found in Africa, Asia, the Balkans, and eastern Europe, causes severe viral haemorrhagic fever outbreaks.

Although a number of tick species are capable of becoming infected with CCHF virus, ticks of the genus Hyalomma, commonly referred to in SA as the “bont-legged ticks”, are the principal vector. The ticks have distinctive brown and white bands on their legs.

In February 1981, the first case of CCHF was recognised in South Africa (SA). To date, there have been nearly 200 cases of CCHF infection in SA with a 20% fatality rate. The majority of cases occurring in SA were in patients from the Northern Cape and Free State provinces.

“The funding that has been awarded will be used to profile immune responses against CCHF viral proteins, and investigate mechanisms and strategies to enhance these immune responses. We hope that the study will contribute knowledge towards the development of a vaccine against this medically significant virus.”

For more information or enquiries contact news@ufs.ac.za.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept